|View printer-friendly version|
Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
“We are honored to receive this recognition, which reflects our commitment to creating a positive and collaborative work environment where employees feel valued and fulfilled,” said
As part of its goal to provide a well-rounded employee experience, Cidara rewards employees for individual performance as well as their contributions toward the company’s strategic goals. Additionally, to drive a strong corporate culture, Cidara has established multiple recognition programs to recognize and reward employees who demonstrate behaviors that support a common set of core principles and organizational values.
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly called CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to